Acute hemolytic transfusion reaction is a life-threatening hematologic emergency caused by transfusion of ABO- or non-ABO antigen-incompatible red blood cells (or less commonly, incompatible plasma), resulting in complement-mediated intravascular hemolysis. [1-2] The root cause is most often failure of patient identification at specimen collection or transfusion. [1-2] Mortality is associated with infusion of ≥200 mL of incompatible blood, though volumes as small as 25 mL have been fatal, particularly in children. [1]
The following figure illustrates the pathophysiology of acute intravascular hemolysis (Panel A) versus delayed extravascular hemolysis (Panel B):
1. History
- Temporal relationship: symptoms onset within minutes to 24 hours of transfusion initiation [1]
- Classic triad: fever, flank/back pain, dark or reddish urine (hemoglobinuria) [1][3]
- Ask about: chills/rigors, anxiety, "sense of impending doom," pain at the IV infusion site, nausea/vomiting, headache, chest tightness [1][3]
- In sedated or anesthetized patients, hemoglobinuria and unexplained shock may be the only signs — maintain high suspicion intraoperatively [3]
- Quantify volume of blood product already infused and rate of infusion [1]
- Verify: Was the correct unit hung for the correct patient? Was there a bedside ID check?
2. Alarm Features
- Hypotension / shock — suggests massive intravascular hemolysis and systemic inflammatory response [1]
- Oliguria or anuria — impending acute renal failure from free heme-mediated tubular necrosis [1]
- Gross hemoglobinuria (red/brown urine) — confirms intravascular hemolysis [1]
- DIC with active bleeding — oozing from lines, petechiae, mucosal hemorrhage [3]
- Sense of impending doom — a well-described early symptom that should not be dismissed [1]
- Rapid progression to multiorgan failure and death if not recognized promptly [1]
3. Medications
- No specific pharmacologic antidote exists; management is supportive [1-2]
- Vasopressors: Dopamine infusion 2–10 µg/kg/min for hypotension [1]
- Furosemide: 40 mg IV bolus, then 10–40 mg/hr continuous infusion (avoid if hypotensive) to maintain urine output [1]
- Sodium bicarbonate: 130 mmol/L in D5W at 200 mL/hr via separate IV line for forced alkaline diuresis (target urinary pH >6.5; discontinue if arterial pH >7.5 or no urinary pH response in 2–3 hours) [1]
- Mannitol is not evidence-based and should be used cautiously, especially in patients with anemia and limited cardiac reserve [1]
- Routine high-dose glucocorticoids, IVIG, and plasma exchange are not supported for standard AHTR, though may be considered in refractory or hyperhemolytic cases [1-2]
- For DIC: platelets, FFP, and cryoprecipitate as needed [1]
4. Diet
- NPO if hemodynamically unstable or if surgical/procedural intervention anticipated
- No specific dietary triggers or modifications relevant to AHTR
- Aggressive IV hydration with isotonic saline is the priority over enteral intake [1]
5. Review of Systems
- Constitutional: Fever, chills, rigors, malaise
- Cardiovascular: Chest pain, palpitations, hypotension
- Respiratory: Dyspnea, tachypnea (may overlap with TRALI/TACO)
- GI: Nausea, vomiting, abdominal pain
- Renal: Decreased urine output, dark urine, flank pain
- Neurologic: Anxiety, sense of impending doom, altered mental status
- Hematologic: New bleeding, petechiae, oozing from IV sites (DIC)
- Musculoskeletal: Back pain (renal capsular distension) [1][3]
6. Collateral History and Family History
- Prior transfusion history: Previous reactions, number of prior transfusions, known alloantibodies
- Pregnancy history: Multiparous women at higher risk for alloimmunization [1]
- Prior transplant history: Allogeneic stem-cell transplant recipients at risk for preformed antibodies [1]
- Hemoglobinopathy history: Sickle cell disease and thalassemia patients at risk for hyperhemolytic reactions [1-2]
- Family history is generally not contributory to AHTR itself
7. Risk Factors
- Clerical/identification errors — the most common cause (wrong blood in tube, wrong patient ID at bedside) [1-2]
- Multiple prior transfusions (increased alloimmunization risk) [1]
- Multiparity [1]
- Prior allogeneic stem-cell transplant [1]
- Hemoglobinopathies (sickle cell disease, thalassemia) — risk for hyperhemolysis [1-2]
- Emergency/trauma settings where verification steps may be bypassed
- Institutions without electronic verification or "zero tolerance" labeling policies [1]
8. Differential Diagnosis
- Febrile non-hemolytic transfusion reaction (FNHTR) — fever/chills without hemolysis; most common transfusion reaction; distinguished by absence of hemoglobinuria, normal haptoglobin, negative DAT [2][4]
- Transfusion-related acute lung injury (TRALI) — acute respiratory distress and bilateral pulmonary infiltrates within 6 hours; no hemolysis [2]
- Transfusion-associated circulatory overload (TACO) — dyspnea, hypertension, pulmonary edema, elevated BNP; no hemolysis [4]
- Allergic/anaphylactic transfusion reaction — urticaria, bronchospasm, anaphylaxis; no hemolysis [4]
- Bacterial contamination/septic transfusion reaction — high fever, rigors, shock; Gram stain and culture of the unit are diagnostic [1]
- Non-immune hemolysis — mechanical (pump), thermal, or osmotic destruction of RBCs; DAT negative [2]
- Autoimmune hemolytic anemia (AIHA) — DAT positive but not temporally linked to transfusion [3]
- Hyperhemolytic transfusion reaction — post-transfusion Hb drops below pre-transfusion level; bystander hemolysis of native RBCs; especially in sickle cell disease [2]
9. Past Medical History
- Prior transfusion reactions (type, severity, management)
- Known RBC alloantibodies
- Sickle cell disease or thalassemia
- Chronic kidney disease (reduced tolerance for renal insult)
- Heart failure (limits aggressive fluid resuscitation)
- Liver disease (impaired coagulation factor synthesis, worsens DIC)
- History of autoimmune conditions
10. Physical Exam
- Vitals: Fever (temperature increase ≥1°C), tachycardia, hypotension, tachypnea [1]
- General: Diaphoresis, anxiety, restlessness, altered mental status
- Skin: Flushing, jaundice (may develop later), pallor
- Cardiovascular: Tachycardia, hypotension, signs of shock
- Pulmonary: Tachypnea, crackles (if fluid overload or ARDS develops)
- Abdomen: Flank tenderness (renal capsular distension)
- IV site: Pain, erythema, or swelling at infusion site [1]
- Urine: Inspect for red/brown discoloration (hemoglobinuria) [1]
- Bleeding assessment: Oozing from lines, petechiae, ecchymoses (DIC) [3]
11. Lab Studies
The following figure illustrates the characteristic time course of laboratory parameters over the first 24 hours after an acute intravascular hemolytic transfusion reaction:
12. Imaging
- No specific imaging is required for diagnosis of AHTR
- Chest X-ray: If respiratory distress is present, to differentiate from TRALI (bilateral infiltrates) or TACO (pulmonary edema, cardiomegaly)
- Renal ultrasound: Consider if oliguria/anuria develops to assess for renal obstruction or cortical necrosis
- CT abdomen: Rarely needed; only if alternative abdominal pathology suspected
13. Special Tests
- Direct antiglobulin test (DAT): The key confirmatory test; a newly positive DAT is pathognomonic. Note: may be negative if antigen-antibody complexes clear before sampling [1]
- Peripheral blood smear: Spherocytes, microspherocytes, schistocytes (if DIC) [1]
- Hemoglobin electrophoresis: In sickle cell patients, serial HbA/HbS fractions to quantify destruction of transfused vs. native RBCs [1]
- Antibody identification panel: To identify specific alloantibody if non-ABO incompatibility suspected [1]
14. ECG
- Obtain ECG in all patients with hemodynamic instability
- Monitor for hyperkalemia-related changes: peaked T waves, widened QRS, sine wave pattern — hyperkalemia is common due to massive RBC lysis and renal impairment [1]
- Tachycardia (sinus) is expected
- Rule out ischemic changes in patients with shock or significant anemia
15. Assessment
Acute hemolytic transfusion reaction is a medical emergency resulting from complement-mediated intravascular hemolysis of ABO-incompatible (or less commonly, non-ABO-incompatible) transfused red blood cells. [1-2] Severity correlates with the volume of incompatible blood transfused and the titer of recipient antibodies, though laboratory testing does not reliably predict severity. [1]
Complications include:
- Acute renal failure (free heme-mediated tubular necrosis and vasoconstriction via NO scavenging) [1]
- DIC with consumptive coagulopathy and hemorrhage [1][3]
- Shock and multiorgan failure [1]
- Death — most fatalities associated with ≥200 mL incompatible blood, though smaller volumes can be lethal [1]
Most reactions are self-limited with prompt recognition and supportive care. [1]
16. Treatment Plan
Immediate actions (first minutes)
- STOP the transfusion immediately — do not flush the line [1-2]
- Keep IV access open with normal saline through a new line [2]
- Save the blood product and tubing for blood bank analysis [1]
- Perform bedside clerical check — verify patient ID against the unit label to interdict a possible second misidentified unit [1]
- Draw blood and urine samples immediately (free Hb clears rapidly) [1]
Supportive care
- Aggressive IV isotonic saline to maintain urine output >0.5–1 mL/kg/hr [1][3]
- Furosemide 40 mg IV bolus → 10–40 mg/hr infusion (if not hypotensive) [1]
- Forced alkaline diuresis: NaHCO₃ 130 mmol/L in D5W at 200 mL/hr via separate line; target urinary pH >6.5 [1]
- Vasopressors (dopamine 2–10 µg/kg/min) for refractory hypotension [1]
- Correct hyperkalemia aggressively (calcium gluconate, insulin/dextrose, kayexalate, dialysis if needed) [1]
DIC management
- Platelets to maintain >20,000/mm³ [1]
- FFP to maintain INR <2.0 [1]
- Cryoprecipitate to maintain fibrinogen >100 mg/dL [1]
Refractory/severe cases
- Plasma exchange may be considered, particularly with large-volume incompatible transfusion, cardiac/renal comorbidities, and macroscopic hemoglobinuria [2][6]
- IVIG and complement inhibitors (eculizumab) have been used in hyperhemolytic reactions, particularly in sickle cell disease [2][7]
17. Disposition
- All confirmed AHTR patients require ICU admission with continuous monitoring and renal consultation, as dialysis may be required [1]
- Observation-level care is insufficient given the risk of rapid deterioration to shock, DIC, and renal failure
- Transfusion medicine / blood bank must be notified immediately for serologic workup and to quarantine any co-components from the same donation [1-2]
- Hematology consultation for complex cases (hyperhemolysis, sickle cell patients, refractory hemolysis) [7]
- Nephrology consultation early, given the high risk of acute kidney injury requiring dialysis [1]
18. Follow Up / Return Precautions
- Mandatory reporting: Report to the institutional transfusion safety committee and, where applicable, to regulatory bodies (FDA for fatalities in the US) [1]
- Document the reaction in the patient's medical record and transfusion history so future crossmatches account for identified antibodies [1]
- Serial labs: Monitor hemoglobin, renal function, coagulation parameters, and urine output q4–6h until stable [1]
- Expected recovery: Most reactions are self-limited with appropriate supportive care; renal function typically recovers, though some patients require temporary dialysis [1]
- Patient counseling: Inform the patient of the reaction, the identified antibody (if applicable), and the importance of carrying a transfusion reaction card or medical alert for future transfusions
- Return precautions (if eventually discharged): Return immediately for fever, dark urine, decreased urine output, new bleeding, or lightheadedness
- Root cause analysis: Institutional investigation into the identification error is essential for prevention [1]
References
1. Hemolytic Transfusion Reactions. — Panch SR, Montemayor-Garcia C, Klein HG. The New England Journal of Medicine. 2019.
2. Transfusion Reactions: Prevention, Diagnosis, and Treatment. — Delaney M, Wendel S, Bercovitz RS, et al. Lancet. 2016.
3. Hematologic Emergencies: Recognition and Initial Management. — Jones DE, Walker JJ, Abellada AMP. American Family Physician. 2024.
4. Epidemiology of Pediatric Transfusion Reactions. — Stone EF, Chacreton D, Jimenez A, et al. JAMA Network Open. 2026.
5. Hemolytic transfusion reactions. — Sandhya R. Panch, Celina Montemayor Rossi's Principles of Transfusion Medicine 6e. 2022.
6. Plasma Exchange in Acute Hemolytic Reaction Due to ABO-incompatible Erythrocyte Concentrate Transfusions: Single Center Experience. — Andıç N, Teke HÜ, Gündüz E. Transfusion Medicine. 2023.
7. American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Transfusion Support. — Chou ST, Alsawas M, Fasano RM, et al. Blood Advances. 2020.